Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Second-generation h1 antihistamines

11 evidence topics · 6 sources

Dose-response network meta-analysis of 211 randomized trials for the Joint Task Force guideline update

“As part of updating the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma & Immunology Joint Task Force on Practice Parameters Chronic Urticaria guidelines, we searched MEDLINE, EMBASE, CENTRAL, and regulatory databases from inception to March 17, 2025, for randomized trials addressing antihistamines or their adjuncts for chronic urticaria.” (opens the source at this quote in a new tab)

“Random effects network and dose–response meta-analyses addressed urticaria activity, angioedema activity, urticaria-related quality of life, and harms including sedation.” (opens the source at this quote in a new tab)

“A total of 211 trials (22,187 participants) evaluated 55 unique treatments. Bilastine, desloratadine, and fexofenadine are among the most effective in overall improvement. Cetirizine and loratadine are among the most effective in reducing overall urticaria activity and its subcomponents, with cetirizine also effective in improving urticaria-related quality of life.” (opens the source at this quote in a new tab)

“Dose–response meta-analyses suggest that there may be diminishing additional benefits beyond standard dosing (Fig 3, A; RD to improve by a minimal important difference with double dose: RD 8 more per 100 participants [95% CI, 7 to 9 more]; quadruple dose: RD 16 more [95% CI, 11 to 20 more]).” (opens the source at this quote in a new tab)

“Second-generation agents may result in a greater reduction compared to first-generation agents (MD −2.51 [95% CrI, −5.01 to −0.02]; RD 10 more [95% CrI, 0 to 19 more]; low certainty).” (opens the source at this quote in a new tab)

Response to updosing among standard-dose nonresponders: systematic review and meta-analysis

“The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We identified 1042 articles and 15 articles were included in the final evaluation. We performed two meta-analyses, one that included studies that analysed treatment response among groups receiving different antihistamine dosages vs. placebo, and another that analysed antihistamine updosing in those patients who did not respond to standard dosages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Only five articles obtained a high quality level score. We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The estimated relative risk for improvement by increasing the antihistamine dosage was 2·27 [95% confidence interval (CI) 1·68-3·06]; however, there was significant heterogeneity. The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote